Our Technology - Automated Processing & Cryo-Storage Technologies - HealthBanks

Our Cell Bank Technology

Our Cell Bank Technology

Automated Processing Technology

Medical Device

ThermoGenesis (Nasdaq:THMO) is a major shareholder of ImmuneCyte. ThermoGenesis is a pioneer in the field of automated cellular processing. Its AutoXpress (AXP) platform is the leading automation technology for all cord blood banks worldwide. More than 1,000,000 automated processing procedures have been performed worldwide.

The Multi-Component Automated Separation System (MCASS™) is a proprietary cGMP compliant, automated system for Immune Cell Processing. It allows simultaneous isolation of different cell components from blood within a closed system, allowing for safe and quality assurance for the future. This system is not available for use at any other US based cell banks. Without using the proprietary and automated technology, immune cells can only be extracted using Ficoll manual method; thus, leading to a higher risk of contamination and cell quality.

Cryo-Storage Technology


Processed cells will be stored in the individualized storage space of our automated storage system BioArchive®. BioArchive® is a leading platform that has been used for storing cell therapies known as BLAs (Biological License Applications), such as cord blood samples approved by the FDA.

Significant Advantages

  • Close automated system for quality
  • Multi-component separation and storage capability
  • cGMP compliant
  • 200ml of blood collection instead of 50ml blood collection, amount required for a single therapy.